$7.9B Non-Small Cell Lung Cancer Market: Just The Tip Of The Iceberg For Benitec's Tribetarna
- NSCLC market is forecast to be worth $7.9B by 2020.
- Benitec's Tribetarna pre-clinical studies shows substantial increases in survival rates.
- Tribetarna is an enhancement to standard chemotherapy, not a replacement for it.
- Tribetarna silences the TUBB3 gene which has been associated with chemotherapy resistance in NSCLC and many other cancers.
- The market for a TUBB3 gene silencing/chemo cancer therapy will be over $20B in 5-6 years time.